Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Cytek Biosciences (CTKB) Invested Capital (2020 - 2025)

Cytek Biosciences (CTKB) has disclosed Invested Capital for 6 consecutive years, with $342.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Invested Capital fell 13.74% year-over-year to $342.3 million, compared with a TTM value of $342.3 million through Dec 2025, down 13.74%, and an annual FY2025 reading of $342.3 million, down 13.74% over the prior year.
  • Invested Capital was $342.3 million for Q4 2025 at Cytek Biosciences, down from $379.2 million in the prior quarter.
  • Across five years, Invested Capital topped out at $427.8 million in Q4 2022 and bottomed at -$11.0 million in Q2 2021.
  • Average Invested Capital over 5 years is $358.7 million, with a median of $395.7 million recorded in 2023.
  • The sharpest move saw Invested Capital surged 40644.2% in 2022, then dropped 13.74% in 2025.
  • Year by year, Invested Capital stood at $405.4 million in 2021, then increased by 5.53% to $427.8 million in 2022, then dropped by 7.74% to $394.7 million in 2023, then rose by 0.53% to $396.8 million in 2024, then decreased by 13.74% to $342.3 million in 2025.
  • Business Quant data shows Invested Capital for CTKB at $342.3 million in Q4 2025, $379.2 million in Q3 2025, and $378.3 million in Q2 2025.